SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (2891)11/19/1997 7:39:00 PM
From: Oliver & Co  Read Replies (1) of 6136
 
BID Dosing study.
Reported at last week's meeting in Miami:
Treatment naive patients, Baseline HIV RNA:194,814 (mean)
Combo with d4T, and 3TC, Viracept 1250 mg BID
At 16 weeks:
Mean reduction of HIV RNA:-2.73 log
Patients with HIV under 400 copies (by PCR): 9/9 (100%)
Mean increase in CD4:+59 cells

Note that Zerit was used. Papers will be presented in Jan, at the antiretroviral meeting re: AZT not a good choice for initial therapy because of resistance pattern, ie:genotypic changes.
Looks that BID Dosing will be comming fast.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News